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Summary.-The cell-mediated cytotoxicity (CMC) of blood mononuclear cells
against cultured human melanoma cells was measured in patients after surgical
removal of localized melanoma, at a time when they were considered on clinical
grounds to be free of melanoma. It was found that the distribution of CMC values
against melanoma cells in melanoma patients was different from that in control
subjects, and several sub-populations of melanoma patients were evident on the
basis of these measurements. No difference in distribution of CMC values was found
against non-melanoma cells, which suggested the changes were specific for
melanoma.
The proportion of patients with recurrence of melanoma was compared between
the patient groups with low, normal or high CMC values against cultured melanoma
cells after surgery. Analysis for periods extending to 2 years showed that patients
with low CMC values after surgery had a significantly higher incidence of recurrence
from melanoma than patients with normal or high CMC values. Theseresultssuggest
there may be a sub-group of melanoma patients who have intrinsically low CMC
against melanoma cells, and that this may be an important predisposing factor in
the development of recurrent melanoma.
SINCE many of the earlier descriptions
of in vitro cell-mediated cytotoxicity
(CMC) against tumour cells by human
blood mononuclear cells (e.g. Hellstrom
et al., 1971), there has been considerable
controversy regarding the specificity and
nature of the effector cells mediating the
cytotoxicity (Baldwin, 1975; Herberman
and Oldham, 1975; Takasugi et al., 1974).
There now appears to be a consensus of
opinion that much of the cytotoxicity of
mononuclear cells from blood of tumour-
bearing subjects is mediated by cells
which are also found in non-tumour-
bearing subjects, and which have natural
cytotoxic specificities for a wide range of
tumour cells (Takasugi et al., 1974, 1977a;
Kiuchi and Takasugi, 1976; DeVriesetal.,
1975; Hersey et al., 1975b; West et al.,
1977).
Whether there are additional cytotoxic
cells which are produced as part of a
specific acquired immune response of the
host to the tumour is still uncertain,
although considerable support for such
additional cytotoxic cells has been found
in melanoma patients by a number of
workers (De Vries and Rumpke 1976;
Steele et al., 1976; Unsgaard and O'Toole,
1975; Mukherji et al., 1975).
What is not clear from the existing
studies is whether either form of CMC
(i.e. naturally occurring or specific ac-
quired) has any prognostic significance in
regard to subsequent growth of the tu-
mour. A number ofstudies in experimental
animals has shown that both specific
CMC (Kirchner et al., 1974; Kiessling et at.,
1974) and naturally occurring CMC
(Becker and Klein, 1976) are depressed by
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growth of tumours. Similar effects on
specific CMC in human subjects have been
described in patients with bladder carci-
noma by O'Toole et al. (1972) and in
melanoma patients by Hellstrom et al.
(1973). More recently, Takasugi et al.
(1977) Pross and Baines (1976) have des-
cribed a similar reduction of natural CMC
in patients with a number of different
carcinomas.
While it is therefore clear that pro-
gressive tumour growth appears to depress
CMC, it is not so clear whether the con-
verse is true, i.e. whether human subjects
with low levels of CMC have a greater risk
of development of tumours, and whether
low levels ofCMC in patients with tumours
predispose them to more rapid spread and
death from their tumours. In the present
study, we have therefore examined the
CMC of melanoma patients considered
clinically free of tumour after surgical
resection of localized melanoma, and have
attempted to correlate these values with
the subsequent incidence of recurrence of
melanoma. The present report of the
interim results ofthese studies on patients
followed for up to 2 years suggests that
low CMC in patients shortly after surgical
removal of localized melanoma appears to
be associated with a higher incidence of
recurrence.
MATERIALS AND METHODS
Patient,s.-Seventy-four patients included
in the study were admitted to the melanoma
unit for complete surgical removal of local-
ized melanoma. Sixteen patients had localized
recurrence of melanoma, but in the others
surgery was for the primary removal of
melanoma. Relevant clinical details of the
patients are described in the Appendix.
Venous blood samples were taken before
surgery, 2-5 weeks after and .3 months
after surgery.
Control subjects in the study were 80
normal laboratory and hospital personnel
whose ages ranged from 20 to 53 (mean 31)
and who comprised 47 females and 33 males.
51Cr-release assays.-Full details of the
assay procedure and expression of results
have been described previously (Hersey et al.,
1975a). The melanoma target cell (TC) was
the MM200 cell line obtained from Dr J. Pope
of the Queensland Institute for Medical
Research. This particular line was derived
initially from a primary melanoma, and in
previous studies was shown to react witlh a
high proportion of melanoma antisera. Both
"melanoma-specific" and "foetal-like" anti-
gens have been defined on its surface. The
control Chaing liver-cell line (Commonwealth
Serum Laboratories, Melbourne, Victoria)
was previously shown not to have, either
melanoma or "foetal-like" antigens on its
surface (Hersey et al., 1975b). Labelling of
target cells was carried out by incubation in
100 ,Ci of Na251CrO4 (Radiochemical Centre,
Amersham, Bucks, U.K.) at 37°C for 2 h.
Effector cells were mononuclear cells ob-
tained by centrifugation ofdefibrinated blood
samples on Hypaque-Ficoll mixtures, accord-
ing to the method of Boyum (1968). Effector:
target cell ratios were 300, 100 and 30:1 in
duplicate cultures in 1 ml of RPMI plus 10%
foetal bovine serum. Incubation was carried
out overnight at 37°C. Percent 51Cr release
was calculated as previously described, and
results were expressed as % 51Cr release above
the % 51Cr release from the target cells alone.
Spontaneous release ranged from 20 to 42%
for the MM200 target cells and 22 to 45% for
the Chang target cells.
Statistical analysis. Comparison of the
proportion of patients without recurrence
from melanoma was made by logrank analysis
(Peto et al., 1977). Differences in the CMC
values of patients at different time intervals
were tested for significance by Student's t
test and findings were considered significant
when P was <0J05.
RESULTS
CMC of effector cellsfrom melanoma
patients and control subjects
CMC values of melanoma patients
against the MM200 TC at 2-5 weeks after
surgery, together with the CMC values of
control subjects at this time, are shown
by the histogram in Fig. 1. (This interval
was chosen for study, as subsequent CMC
values were influenced by the chemo-
immunotherapy given to some of the
patients, and we believe the pre-surgery
values may have reflected influences on
the CMC of the growing melanoma cells
and hence not the true intrinsic levels of
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FiG. 1.-Distribution of CMC values of blood
mononuclear cells from (a) melanoma
patients 2-5 weeks after removal of local-
ized melanoma and (b) control subjects
against the MM200 target cell (TC). The
shaded areas indicate the CMC values of
patients with melanoma who subsequently
had recurrence from melanoma. Effector:
target cell ratios 100:1.
CMC of the patient.) The distribution of
CMC values for normal subjects was a
skewed normal distribution with a mean
of 14-97 and a standard error (s.e.) of 5-78.
The distribution of CMC values for the
melanoma patients was different from
that of the controls, and peak distribution
of CMC values was seen at 5-9% 51Cr
release, with a smaller peak at 30-34%
51Cr release. (The proportion of melanoma
patients with CMC values 10% 51Cr re-
lease was 0 39, compared with 0-24 for the
control subjects.) This suggested that
there may be different subpopulations of
patients with respect to their CMC values.
The CMC values of patients who re-
lapsed in the study period are also shown
in Fig. 1 by the shaded areas. Seven
patients with recurrence oftheirmelanoma
had 5lCr-release values <10, 2 had values
15-19 and 2 had values >20. Reference
to the Appendices indicates that patients
with values < 10 with recurrence from
melanoma appeared to be comparable
to those with CMC values >10 in
terms of age, sex and history of previous
melanoma.
CMC values of the control subjects and
melanoma patients were also compared
with cells from the control Chang cell line
as shown in Fig. 2. Both normal subjects
and melanoma patients showed a skewed
30
25
20
mIs
LI'15
LL-
0
10
of
m
: 5
z
0
- a. b.
/I
0 10 20 30 0 10 20 30
PERCENT Cr RELEASE
FIG. 2. Distribution of CMC values of blood
mononuclear cells from (a) melanoma
patients and (b) normal controls against the
Chang TC's (as for Fig. 1). The shaded areas
again indicate the patients who sub-
sequently had recurrence from melanoma.
Effector:target cell ratios 100:1.
normal distribution, with means of 9-56± 5.4 (s.e.) for controls and a mean of 9-87±
4*3 for melanoma patients. No difference
was seen in distribution of CMC values of
the two populations against the Chang
cells. These results appeared to indicate
that the different distribution of the CMC
values of melanoma patients against the
MM200 TC, when compared to control
subjects, may have reflected changes
which were specific for the melanoma
cells.
The different specificity of the CMC of
melanoma patients from that of the con-
trols was also shown by comparing their
CMC against the melanoma cells and the
Chang cells. If the specificity ofCMC were
the same against both target cells, the
ratio, CMC against MM: 200 CMC against
Chang would be constant, irrespective of
the actual CMC values. This was the find-
ing with the CMC of normal subjects,
where the ratio was 1-8 at all levels of
absolute CMC values. However, in mela-
noma patients the ratio changedmarkedly,
depending on the level of the CMC values
against the MM200 TC. Patients with
CMC values <10 had ratios of0 9, whereas
those with values of 10-20 and >20 had
ratios of 1-8 and 5.8 respectively.
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FIG. 3. Cumulative proportioni of patients
free of recurrence from melanoma after
surgical removal of localize(l melainoma.
The recurrence rate for all patients is
shown together with the recturrence rate for
patients subdivided on the basis of their
CMC values against the MM200 TC after
surgery. These groups are indicated by the
figures at the end of the lines in the figure.
Relation of C0IC values to recurrence front
melanoma
On the basis of the hypothesis that the
different distribution of CMC values of
melanoma patients against the MM200
TC may have indicated different sub-
populations of melanoma patients, the
recurrence rate from melanoma was com-
pared in patients with CMC values that
were either within, greater or less than
1 s.e. from the mean CMC value of the
control subjects (viz. 10-20, >20 or <10,
respectively). The cumulative proportion
of patients free of recurrence from mela-
noma is shown in Fig. 3 for these sub-
groups and for all the patients in the
study. The patients with low CMC had a
higher incidence of recurrences than
patients with normal or high CMC values,
which was significantly different by log-
rank analysis (P<0-025, 2 d.f., or P<
0-025, 1 d.f.) with the comparison between
patients with low CMC values and the
sum of patients with normal (10-20) and
high (>20) CMC values. There was no
difference in the recurrence rate from
melanoma between patients with normal
or high CMC values.
Sequential changes in CMC values of
melanoma patients
CMC values of the effector cells from
the above groups of patients in the study
before surgery and 2-3 months after
surgery are shown in the Table. There
was a tendency for the patients with low
CMC values after surgery (<10% 51Cr
release) to also have low values before
surgery, but these were not significantly
different from the CMC values ofthe other
patients before surgery. Pre-surgery values
were, however, significantly higher than
the CMC values for this group after
surgery (P<0 001). Conversely, patients
with high (>20% 51Cr release) CMC after
surgery also had normal values before
surgery, indicating that this group had a
significant elevation (P<0.001) in CMC
after surgery. CMC values 3 months after
surgery were not significantly different in
the 3 groups, but the mean values still
had the same relationship to each other
as at 2-5 weeks after surgery. The dif-
ferent treatments given to the patients
after surgery (see Appendix) may have
had a marked influence on the CMC values
at this interval, and we believe that this
makes interpretation of the data at this
time more difficult.
Mononuclear cells from control subjects
were tested in all assays, in parallel with
mononuclear cellsfrom melanomapatients,
and no significant changes in the CMC of
the control subjects were noticed in the
sequential studies against either the MM-
200 or the Chang TC. Further evidence
that the sequential changes noticed in the
CMC values of melanoma patients against
the melanoma TC were true biological
changes and not chance variation can be
seen by reference to the CMC values ofthe
patients against the control Chang cell in
the Table. No significant differences in the
CMC values in the patient groups were
noticed at any of the time periods of the
study.
DISCUSSION
Although the duration of this study is
still relatively short and the number of
patients with recurrences is still small, the
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TABLE. Sequential Changes in CMC Values of Effector Cells from Melanoma
Patients
CMC against MM200
Subgroup*
0-9 Mean
s.e.
10-20 Mean
s.e.
>20 Mean
s.e.
Controls Mean
s.e.
1-2 days
before surgery
10-7 (a)
6-2
14-8
6-1
15 2 (c)
50
12-54
4-7
2-5 weeks 8-12 weeks
after surgery after surgery
6.3 (b) 15-6 (a)
1-9 5 0
15-1 16-7
2-0 40
28-4 (d) 25-3
5-2 8 0
14-9 14-4
5-8 4-6
1-2 d
before sl
7-7
4 0
9-7
5 0
6-0
2-9
9.0
4-2
CMC against Chang cells
lays 2-5 weeks 8-12 weeks
urgery after surgery after surgery
8-5 10.0
3-3 5.3
11-8 11-3
5-1 5-7
9-8
5-1
9-6
3-5
10-2
5-5
9.9
4 0
* Subgroups as for Fig. 3 above based on CMC values against MM200 2 5 weeks after surgery, and repre-
sent values within 1 s.e. of the mean cointrol CMC values or greater or less than this. Figures in the tables
are % 51Cr release above baseline (51Cr release from TCs alone). Effector:target cell ratios 100:1.
(a) Significantly greater than (b) (P<0-001). (d) Significantly greater than (c) (P<0-001).
results suggest an association between low
CMC values against cultured melanoma
cells in patients after surgical removal of
their melanoma and the subsequent re-
currence of melanoma.
One of the main problems in inter-
preting these results was to know the
extent to which the patients were free of
tumour after apparent complete surgical
removal. This is important in that several
previous studies, including those on CMC
referred to in the introduction, have shown
that various aspects of cell-mediated im-
munity appear to be suppressed as a
result of tumour growth (Southam, 1968;
Twomey et al., 1974; Anthony et al., 1975;
Cochran et al., 1975; Oldham etal., 1976).
This question is clearly difficult to re-
solve in the absence of reliable tumour
marker assays in melanoma. However, we
believe that suppression of CMC by pre-
existing tumour does not explain our
results. Firstly, on clinical grounds there
was no reason to believe that patients
with low CMC had more residual tumour
than those with high CMC. Secondly, most
of the studies referred to have shown that
depression of cell-mediated immunity oc-
curred only in patients with advanced,
clinically obvious, malignancies, and was
not a feature of patients with localized
disease. These points therefore argue
against the low CMC being the result of
pre-existing tumour, and suggest instead
that the low CMC may have been one of
the predisposing factors in development of
recurrences in these patients. Natural
CMC activity of blood mononuclear cells
in mice has been shown to vary between
strains and to be an inherited trait
(Kiessling et al., 1975). It is possible that
the low levels of CMC of the blood mono-
nuclear cells in the patients in this study
may represent a similar group of subjects
who have low levels of CMC on a genetic
basis. The possible genetic basis of the
low natural CMC is favoured by our recent
findings that members of several families
with a high incidence of melanoma had
low or absent CMC against melanoma
cells (manuscript in preparation).
The distribution of CMC values of
melanoma patients against the melanoma
TCs was different from that of the control
subjects. This difference between the CMG
ofmelanoma patients and control subjects
was not evident against the control
Chang TC and suggested that the specifi-
cities of natural CMC in the two groups
were different. These results are com-
patible with recent studies showing that
natural CMC does exhibit specificity to
different tumour cells (Takasugi et al.,
1977b; Bonnard et al., 1977). Whether the
difference in specificity of the CMC de-
tected in our own studies was restricted
to melanoma cells would require assays
against a wider range of target cells than
we have found practicable in routine
studies.
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Not all our findings, however, seem to be
entirely explicable in terms of natural
cytotoxicity by the blood mononuclear
cells. The fall in CMC after the surgical
removal of melanoma in the group with
low CMC before surgery may have in-
dicated a decrease in specific acquired
CMC above the intrinsic low levels of
natural CMC of the effector cells in these
patients. The reason for the rise in CMC
noted after surgery in the patients with
high CMC before surgery is not immedi-
ately apparent, but may indicate that the
CMC in these patients was suppressed by
factors released by the growing tumour.
Removal of the tumour may then have
allowed the natural CMC to return to the
former normally high levels. Whether or
not the interpretation of these changes is
correct, it is clear that these sequential
changes were relatively specific to the
melanoma cell, in that similar changes
were not seen against the control Chang
TC, and the natural CMC of normal sub-
jects tested in parallel did not undergo
similar changes against either target cell.
Relatively few studies have shown that
immunological parameters have a prog-
nostic bearing on the course ofsubsequent
tumour growth in tumour patients. The
classical study ofEilber and Morton (1970)
showed that the ability of tumour-
bearing patients to be sensitized to dinitro-
chlorobenzene correlated with the sub-
sequent course of tumour growth. These
results, however, may have reflected the
influence of the tumour on the skin test
response and not the intrinsic immuno-
logical competence ofthe host. The studies
of Twomey et al. (1974) would support
this view, in that they found that "cured"
cancer patients had skin-test reactivity
similar to normal subjects and much
higher than an equivalent group of
patients before surgical removal of their
tumour. Similarly, Hersh et al. (1975)
using lymphocyte blastogenesis inresponse
to melanoma antigens, found that the
degree of blastogenic response to mela-
noma antigens could be correlated with
the subsequent prognosis in patients with
melanoma.
The study perhaps most analogous to
our own was that of Veronesi et al. (1973)
who correlated the results of microcyto-
toxicity tests on 18 Stage I & II melanoma
patients with the duration to recurrence
from melanoma. No correlation was found
in this study between the presence or
absence of CMC to melanoma and the
duration to recurrence.
Whether our contention that the present
results reflect the measurement of an
intrinsic tumour-control mechanism is
correct, obviously requires more extensive
and prolonged studies of the melanoma
patients, supported where possible by
studies on families at risk from develop-
ment of melanoma (Anderson, 1971). If
these initial findings were substantiated
in these further studies, the present results
would appear to have implications for
immunotherapy ofthose patients detected
to be at risk because of low natural CMC
activity, in that therapeutic measures to
increase the levels of CMC may be indi-
cated in this group of patients. Measure-
ment of natural CMC levels against
melanoma cells may therefore provide the
basis for a more selective and rational
approach to immunotherapy of tumour-
bearing patients.
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APPENDIX.-Details of Melanoma Patients Grouped according to CMC 2-5 Weeks
after Surgery
Name
LC
OD
GD
SD
MG
FG
CH
DJ
KJ
BJ
EM
IM
HM
WB
IP
RP
IR
KR
GS
DW
Cs
RS
KZ
SM
GD
WF
FH
GA
RB
JG
PA
Name
BB
AC
GO
SD
LF
JG
GH
TH
PH
LJ
TL
GM
MS
BW
Mc
GA
MD
RA
MS
Age
70
67
79
22
53
39
74
26
55
53
60
24
41
47
70
33
28
56
42
43
25
66
45
38
50
75
35
56
68
36
30
33
Age
36
22
72
56
39
48
59
72
32
19
29
37
40
41
19
54
75
34
26
Sex
M
M
M
F
F
F
M
M
M
M
F
M
M
M
F
M
M
F
M
F
M
M
F
M
F
M
M
M
M
M
F
M
Sex
M
M
M
M
F
F
M
M
F
M
M
M
M
F
F
M
F
F
F
Clinical
stage
2
2
1
1
2
1
2
2
2
1
2
1
2
1
1
2
2
1
1
1
2
1
1
1
2
1
1
2
1
1
1
2
Clinical
stage
2
1
2
2
1
2
1
2
1
2
1
1
1
1
2
2
2
1
2
CMC <10
Previous
surgery for
melanoma
(months)
17
14
3
4
60
4
8
10
CMC 10-20
Previous
surgery for
Melanoma
(months)
33
80
5
120
18
Months to
recurrence
2
11
10
30
16
6
2
Months to
recurrence
8
11
Months to
death
9
10
22
13
Months to
death
C & I = chemoimmunotherapy with imidazole carboxamide and BCG vaccination.
B = immunotherapy with BCG vaccination.
C = chemotherapy alone.
Treatment
after surgery
C & I
a & I
C &; I
C &; I
C &r I
C & I
B
B
B
Treatment
after surgery
c
C &s I
B
C &; I
C &; I
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APPENDIX (cont.)
CMC >20
Previous
surgery for
Clinical melanoma Months to Months to Treatment
Name Age Sex stage (months) recurrence death after surgery
NN 25 M 1 - -
JP 25 F 1
HB 46 M 1 C &- I
SP 68 M 1 - C & I
JP 35 M 1 -
CR 29 F 2 7
JS 36 F 2 30 - C & I
PS 46 F 1 B
KS 62 M 1
DT 24 M 2 - - C&I
VB 71 M 2
CA 52 M 2 - - B
AB 50 M 1
PC 50 M 2 - - -
CC 55 M 2 5 C& I
LH 61 F 1 - -
All 65 F 2 48 5 - C& I
NK 65 F 1 - I _
CM 29 F 1
BS 60 M 1
AB 40 F 1
WF 37 M 1 - _
EW 62 M 1 -
C & I = chemoimmunotherapy with imidazole carboxamide and BCG vaccination.
B = immunotherapy with BCG vaccination.